CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study von Frank, Matthew J, Baird, John H, Kramer, Anne Marijn, Srinagesh, Hrishikesh K, Patel, Shabnum, Brown, Annie Kathleen, Oak, Jean S, Younes, Sheren F, Natkunam, Yasodha, Hamilton, Mark P, Su, Yi-Jiun, Agarwal, Neha, Chinnasamy, Harshini, Egeler, Emily, Mavroukakis, Sharon, Feldman, Steven A, Sahaf, Bita, Mackall, Crystal L, Muffly, Lori, Miklos, David B, Klysz, Dorota Danuta, Gkitsas-Long, Nikolaos, Bacigalupi, Juliana, Iglesias, Maria, Crawford, Emma, Nichols, Linnea, Cunanan, Kristen, Tamaresis, John, Spiegel, Jay Y., Ehlinger, Zachary, Kuo, Adam, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen Kai, Bharadwaj, Sushma, Dahiya, Saurabh, Smith, Melody, Schultz, Liora M., Ramakrishna, Sneha, Davis, Kara L., Tunuguntla, Ramya

Volltext